Results 111 to 120 of about 5,969 (169)

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies. [PDF]

CNS Drugs
Dzamko N.
europepmc   +1 more source

Erratum: Ambroxol enhances anti-cancer effect of microtubule-stabilizing drug to lung carcinoma through blocking autophagic flux in lysosome-dependent way. [PDF]

Am J Cancer Res
Zhang X, Chen Q, Chen M, Ren X, Wang X, Qian J, Sun Y, Sha X.   +7 more
europepmc   +1 more source

Exploring the long-term use of ambroxol in Gaucher disease type 2: insights from two pediatric cases. [PDF]

Front Neurol
Aries C, Köhn A, Täuber K, Rudolph C, Böttcher T, Bauer P, Fischer S, Muschol N.   +7 more
europepmc   +1 more source

Ambroxol mitigates cyclophosphamide-induced liver injury by suppressing TLR-4/NF-κB signaling and oxidative stress and upregulating cytoglobin, TXNRD1 and HMGB1. [PDF]

World J Gastroenterol
Alruhaimi RS, Hassanein EHM, Alnasser SM, Ahmeda AF, Althagafy HS, Abd El-Ghafar OAM, Mahmoud AM.   +6 more
europepmc   +1 more source

Prescription of EPs 7630 is associated with short- and long-term benefits in acute bronchitis: a real-world data analysis. [PDF]

Front Pharmacol
Gillissen A, Reineke T, Burkart M, Funk P, Adarkwah CC, Kostev K.   +5 more
europepmc   +1 more source

Treatment Patterns, Cough Formulations, and Antibiotics Usage for Pediatric Acute Cough in India: A Real-World Study. [PDF]

J Pharm Bioallied Sci
Jindal SK, Vora A, Malve H, Panchal R.
europepmc   +1 more source

Ambroxol displaces α-synuclein from the membrane and inhibits the formation of early protein-lipid coaggregates. [PDF]

Chem Sci
Dreier JE, Stevenson A, Carles E, Schott K, Michaels TCT, Galvagnion C.   +5 more
europepmc   +1 more source

N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care. [PDF]

Drugs Context
Benedetti F, Santus P.
europepmc   +1 more source

LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson's Disease Patients. [PDF]

Int J Mol Sci
Franco V, Palmisani M, Colucci F, De Micco R, Aloisio S, Cazzaniga F, Cerri S, Crema F, Dattrino F, Garavaglia B, Gastaldi M, Mitrotti P, Moda F, Rota P, Stiuso R, Tassorelli C, Eleopra R, Tessitore A, Valente EM, Avenali M, Cilia R.   +20 more
europepmc   +1 more source

Uso de amoxicilina suspensión de 250mg/5ml para el tratamiento de neumonía en niños de 2 meses a 5 años procedentes de la zona sur de Masaya atendidos en el Centro de Salud Monimbó, Mayo-Octubre 2013 [PDF]

, 2014
Briceño Noguera, Claudia Cecilia, Lezama Somoza, Adriana de los Angeles, López López, Meyling del Rosario   +2 more
core